OPKO completes sale of BioReference oncology assets to Labcorp for $192.5M cash plus earnout

OPKO HEALTH, INC.

Transaction closed Sept 15, 2025; Labcorp paid $192.5M at closing, with up to $32.5M earnout.
Assets include BioReference's oncology and oncology-related clinical testing services across the U.S.
OPKO to use portion of proceeds for share repurchase; continuing ops had ~$300M revenue in 2024.
CEO Phillip Frost says deal positions BioReference to focus on core testing and 4Kscore franchise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.